Merck Seeks Oxytrol Switch For Women As First Overactive Bladder OTC

 
• By Dan Schiff

Merck will present to FDA’s Nonprescription Drugs Advisory Committee Nov. 9 in support of switching Watson’s Oxytrol as a female-specific OTC.

Merck & Co. Inc. aims for uncharted OTC territory with a new drug application to switch overactive bladder drug Oxytrol to nonprescription sale.

Should it succeed, the Oxytrol transdermal system (oxybutynin 3.9 mg), licensed from Allergan PLC, would be the first first-in-class...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from US FDA Performance Tracker

More from Regulatory Trackers